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Poster Session I 45that included all autologous HPC Transplant (HPCT) patients
with hematological malignancies seen by our HPCT program
from February 2003 to January 2007. Costs were compiled from
the Institution’s Charge Description Master and included costs
from additional filgrastim administration through collection.
The threshold was increased incrementally from 4 to 9 CD341
cells/ml to determine the most cost effective strategies while max-
imizing the number of successful collections. Results: There were
302 autologous patients with 463 peripheral CD34 assays and 572
collections. Of these, 149 patients and 322 observations had
CD341 counts\21 CD341 cells/ml. 175/322 were assays with
collections, while 147 were assay only. The analysis of the decision
tree indicates that at a CD341 level of 7, the costs of the collection
are moderately reduced by 3.3%, and 87% of the patients meet the
minimum cell goal. At a level of 8 CD341 cells/ml, the costs are re-
duced 4.5% and 100% of patients meet the minimum cell goal.
Discussion:The results suggest that the most cost effective collec-
tion occurs at peripheral CD341 count of 8 CD341 cells/ml or
above. This is not unexpected, as better collectors have fewer col-
lections. However, this results in an unacceptably high number of
patients that will fail to collect.116
DETERMINING FINAL APHERESIS VOLUME FOR HEMATOPOIETIC PRO-
GENITOR CELL (HPC) COLLECTION BASED ON INTRA-PROCEDURAL
SAMPLING
Hackett, M., Rahn, D., Smilee, R.C., Anasetti, C., Fernandez, H.,
Janssen, W.E. H. Lee Moffitt Cancer Center, Tampa, FL.
When collecting HPC by apheresis, sufficient CD34 cells must
be collected to effect a timely and stable graft. Donor safety must
also be protected, requiring that apheresis not be longer than nec-
essary. A correlation between circulating and collected CD34 cells
has been reported, but variability between donors in apheresis col-
lection efficiency may limit the accuracy of this measure for deter-
mining blood volume to process. Apheresis efficiency and
circulating CD34 cell levels must be similar throughout the collec-
tion procedure. Thus, we hypothesized that CD34 cell collection,
measured early in the apheresis process, could be used to extrapolate
the final apheresis volume needed to meet collection targets. In 47
normal HPC donors, undergoing apheresis using the Gambro
Spectra and PBSC protocol version 6.1, the collection bag was sam-
pled after one (n 5 18) or two (n 5 29) total body blood volumes
(TBV) had been processed. CD34 cells collected was determined,
and total apheresis volume was projected as:
Final apheresis vol. 5 vol. at sampling  [CD34 required/CD34
at sampling]
To insure adequate collection, apheresis was continued until
a blood volume at least 10% greater than projected was processed.
Even so, three collections (6%) failed to meet targets. To determine
the validity of the hypothesis that CD34 count at early sampling
predicts final CD34 content, dependent only on apheresis volume,
expected CD34 content for the final volume actually collected was
computed as
Expected CD34 5 sample CD34  [vol. collected/vol. at
sampling]
and was compared to the observed final CD34/Kg content. Using
simple linear regression and correlation analysis to measure the
strength of the association between the expected and the observed
CD34/Kg content, significant linearity between expected CD34
content and observed CD34 content for both 1xTBV and 2xTBV
sampling was found, with Pearson correlation coefficients of
0.914 and 0.945 respectively. F-test revealed p\0.0001 for projec-
tions from both sampling intervals. In comparison, similar analysis
comparing projected CD34 collection from circulating CD34 cells
yielded a Pearson correlation coefficient of 0.754 with F-test p\
0.0001. These results support the practice of using the CD34 con-
tent of samples drawn from partially collected products, as early in
apheresis processing as 1–2TBV, to compute the necessary donor
blood volume to process to achieve sufficient HPC collection with-
out undue risk to the donor.117
CHARACTERISTICS AND CELL COMPOSTION OF PRIVATELY BANKED
AUTOLOGOUS UMBILICAL CORD BLOOD (UCB) UNITS UTILIZED FOR
AUTOLOGOUS UCB INFUSION IN CHILDREN WITH TYPE 1 DIABETES
Smith, L., Haller, M.J., Staba Kelly, S. University of Florida, Gaines-
ville, FL.
Private cord blood banks process and store umbilical cord blood
(UCB) for potential future use by that child or perhaps a sibling.
Despite increasing numbers of UCB units banked in private banks,
very few have ever been used besides those banked intentionally for
siblings with high risk malignancies or other diseases treated with
stem cell transplant (SCT). There is high variability in the charac-
teristics, cell dose, as well as processing and storage of the UCB
units in these banks. Families pay fees for the banking and continued
storage of the units, unaware of the number of cells or other char-
acteristics of the UCB unit that is banked. At the University of Flor-
ida a study of autologous UCB infusion in children with newly
diagnosed type 1 diabetes (T1D) is underway. Children with T1D
who happened to have UCB stored at birth received an infusion
of their autologous UCB that was thawed in standard fashion.
The UCB units were all tested prior to infusion for viability, steril-
ity, and identity confirmation via HLA typing, and standard cell
enumeration and flow cytometry were performed. Twelve children
have had their autologous UCB infused at a median age of 6 (range
2–10) years. Eleven of the UCB units were stored in 8 private banks
and 1 unit had been donated to a public bank and was retrieved for
the study. The median weight of patients was 24 (range 12–45) kg.
The average nucleated cell dose per kilogram infused was 1.89 107
(range 0.27–4.39), with an average CD34 dose per kilogram of 4.4
104 and viability of 96%. At most transplant centers, the minimum
desired cell dose for standard UCB transplant is 3 107 per kg body
weight. Of the 12 UCB units, only 3 would have exceeded this min-
imum, despite the fact that the average weight was only 24 kg. One
of the 3 units of sufficient size was the unit that had actually been
banked in the public bank. In addition, half of the units were stored
in cryovials ranging from 0.5 ml to 5 mls. The vials leave no room to
add any media for the thawing process. This resulted in a 15% de-
crease in recovery when compared with units stored in bags. In ad-
dition, the risk of bacterial contamination is higher when the cells
are in vials and have to be transferred to larger vials or bags for pro-
cessing and infusion. Private UCB banks advertise to families to
store a child’s UCB for future use, charging a significant fee, how-
ever it appears that many units may be under the acceptable cell dose
for standard transplant.
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ELEVATED CD141 CELL DOSE IN MARROW GRAFT CORRELATES WITH
INCREASED MORTALITY AFTER ALLOGENEIC TRANSPLANTATION
Arpinati, M.1, Chirumbolo, G.1, Nicolini, B.1, De Vivo, A.1,
Bonifazi, F.1, Giannini, M.B.1, Bandini, G.1, Martelli, V.1,
Stanzani, M.1, Baccarani, M.1, Rondelli, D.2 1University of Bologna,
Bologna, Italy; 2University of Illinois at Chicago, Chicago, IL.
Background: The role of donor antigen presenting cells (APC)
in human bone marrow grafts in post-transplant clinical outcome
is not well established, although data from animal models suggest
that they may regulate GVH responses and immune reconstitution
early after transplant. Aim: In this retrospective study we tested
whether marrow composition of donor APC was associated with
outcome after allogeneic transplantation. Patients and Methods:
81 consecutive patients undergoing allogeneic bone marrow trans-
plantation in our institution from June 1999 through June 2006
were analyzed, provided that graft composition data were available.
All but 1 patient received the marrow from HLA matched unrelated
donors. Of 81 patient, 67 received a myeloablative and 14 a reduced
intensity conditioning regimen. ATG was also administered in 79/
81 patients. Graft numbers of CD11c1 myeloid DC (mDC),
CD1231 plasmacytoid DC (pDC) and CD141 monocytes were
determined based on flow cytometry analysis. Results: After a me-
dian follow up of 346 days (interquartile 132–968), the following
transplant-related events were recorded: acute GVHD II-IV in 18
and extensive chronic GVHD in 22 patients and relapse in 19 pa-
tients. Transplant-related mortality (TRM) occurred in 23, and re-
lapse-related mortality in 12 patients. Patients were divided based
46 Poster Session Ion median donor graft mDC (0.81  106/kg recipient weight), or
pDC (0.67  106/kg), or monocyte (6.6  106/kg) counts. No cor-
relation was observed between acute and chronic GVHD as well as
relapse and APC counts. However, the mortality rate was signifi-
cantly higher in patients who received a greater dose of monocytes
(24/41 vs 11/41) (p5 0.003), with a trend for a more elevated TRM
(15/41 vs 8/41) (p 5 0.08), as compared to patients who received
a lower dose of monocytes. mDC and pDC counts did not correlate
with survival after transplant. In univariate analysis, TRM corre-
lated with advanced disease (p 5 0.03), age (p 5 0.039) and graft
monocyte and T cell counts (both p 5 0.03), whereas overall mor-
tality correlated with advanced disease (p\0.0001) and graft mono-
cyte counts (p 5 0.02). In multivariate analysis, monocyte counts
correlated with both TRM (p 5 0.06) and overall mortality (p 5
0.01). Conclusion: Donor CD141 cell dose in bone marrow grafts
independently correlates with mortality following allogeneic trans-
plantation suggesting a possible role of donor mature accessory cells
in the regulation of post-transplant immunologic events.
119
CLINICAL ISOLATION AND EX VIVO CULTURING OF CORD BLOOD-
DERIVED T CELLS FOR DONOR LYMPHOCYTE INFUSION
Uhlin, M.1,2, Ringden, O.2, Mattsson, J.2 1Karolinska Institute, Stock-
holm, Sweden; 2Karolinska Institute, Stockholm, Sweden.
Umbilical cord blood (CB) is a promising source of hematopoie-
sis for patients lacking a human leukocyte antigen (HLA)-matched
donor. CB can be collected easily and safely, is readily available, and
leads to successful long-term engraftment. Greater HLA disparity
can be tolerated between the recipient and donor CB compared
with bone marrow (BM) or peripheral blood (PB). CB T cells are
naive and express an immature phenotype, and CB grafts have lower
total nucleated cell (TNC) doses compared with BM. These factors
contribute to delayed time to engraftment and poor immune recon-
stitution in CB recipients.
CB transplantation has also been reported to be associated with
a lower risk of graft-vs-host disease (GVHD), which then reduces
the graft-vs-leukemia (GVL) effect. T cells are believed to be respon-
sible for the GVL effect. These cells now are used clinically as donor
lymphocytes to control minimal residual disease or reinduction of re-
mission in relapsed leukemia after Allogenic bone marrow or periph-
eral blood (PB) stem cell transplantation. It has been shown that
Allogenic ex vivo expanded suicide gene-modified PB T cells also
have the potential to cause GVHD and GVL effects. This raised
the question of whether ex vivo expanded CB lymphocytes (CBL)
also can be used as a tool for adoptive cellular immunotherapy.
PreliminaryResults:We have just recently managed to establish
a protocol for massive expansion of CB derived T cells. We have
been able to show that cells can be expanded very efficiently more
then 100 fold, making them usable in the clinic suitable in number
for DLI after CB transplantation. We have further shown that the
expansion protocol doesnt skew the T cell population regarding
the phenotype, CD4:CD8 ratio as well as TCR usage profile. By ac-
tivating the expanded cells we have further confirmed the expanded
T cells capacity to efficiently produce pro-inflammatory cytokines.
Clinical Significance: Cord blood is increasingly used as stem cell
source in allogeneic SCT. However, in patients with malignant dis-
ease we hesitate to use CB since there is no possibility to increase the
GVL effect after CB SCT. If we can develop methods for expansion
of donor T cells from the CB unit given to the patient this may have
a dramatic impact on the treatment of rejection and relapse of the
underlying disease after CB transplantation. Today we lack treat-
ment options if the patient is showing signs leukemia relapse or re-
jection after CB transplantation.HEMATOPOIESIS/MESENCHYMAL CELLS120
GLYCOSAMINOGLYCANS AS ANTICOAGULANTS IN MUCOPOLYSAC-
CHARIDOSIS TYPE I (MPS I)
Tolar, J.1, Orchard, P.J.1, Key, N.2, Blazar, B.R.1 1University of
Minnesota, Minneapolis, MN; 2University of North Carolina School of
Medicine, Chapel Hill, NC.MPS IH (Hurler syndrome) is caused by severe mutations in
a-L-iduronidase (IDUA) gene, leading to accumulation of glycos-
aminoglycans (GAG). The disorder is lethal unless treated with he-
matopoietic stem cell transplantation (HSCT). When compared to
other recipients of HSCT, MPS IH patients have an increased inci-
dence of bleeding complications. To investigate whether this bleed-
ing propensity is related to the GAG accumulation we evaluated five
MPS IH patients (mean age: 1.1 years) prior to any therapy. We ob-
served that three of the five patients had an elevated activated partial
thromboplastin time (aPTT). We reasoned that the accumulation
of heparin sulfate, a hallmark of MPS IH, may serve as a heparin-
like anticoagulant. Consistent with this assumption, we have ob-
served a clear dose – effect relationship between GAG load and level
of anticoagulation. In this context, it is important to note that the
patient with the second highest value of urinary GAG and aPTT ex-
perienced pulmonary bleeding on day 12 after HSCT requiring in-
tubation and ventilatory support for 25 days. We hypothesized that
endogenous GAG heparin sulfate exerts its antithrombotic effect
through inhibition of factor Xa. To test this hypothesis, we have as-
sessed anti-Xa levels in mice with IDUA deficiency, an animal
model of MPS IH. As expected, the anti-Xa level were not signifi-
cantly different in wild type C57Bl/6 mice and heterozygous
mice: 0.116 0.005 IU/cc plasma versus 0.106 0.004 IU/cc plasma
(p 5 0.2). Anti-Xa values of MPS IH mutant mice, however, were
significantly elevated when compared to the age-matched sex-
matched wild type controls (0.196 0.05 IU/cc plasma versus 0.116
0.005 IU/cc plasma; p\0.001). In addition, we have observed that
GAG anticoagulant activity was neutralized by addition of the hep-
arinase. In conclusion, the current study links GAG produced in ex-
cess as a result of IDUA deficiency and a hemostatic defect in MPS
IH mice and humans. The implications of the current study are that
an impaired hemostasis may exist in untreated patients with MPS
IH, and that MPS IH patients with high urinary GAG are likely
to experience bleeding complications. This information may be use-
ful in identifying MPS IH patients at higher risk for bleeding, espe-
cially in the peri-transplant period, when GAG levels have not yet
normalized and additional, HSCT-related factors (e.g., thrombocy-
topenia and hepatic dysfunction affecting clotting factors) contrib-
ute to the high risk of bleeding.121
INTERACTION OF CD41CD251FOXP31 REGULATORY T CELLS WITH
HEMATOPOIETIC PROGENITOR CELLS REVEALS TWO DISTINCT PATH-
WAYS OF REGULATION
Urbieta, M.1, Barao, I.2, Chirinos, J.1, Panoskaltsis-Mortari, A.3,
Blazar, B.R.3, Murphy, W.J.2, Levy, R.B.1 1University of Miami School
of Medicine, Miami, FL; 2University of Nevada, Reno, NV; 3University
of Minnesota, Minneapolis, MN.
Naturally occurring CD41CD251Foxp31 regulatory T (Treg)
cells are responsible for a physiologically essential peripheral mech-
anism to maintain self tolerance. Several Treg cytokines which me-
diate immune regulation concomitantly possess hematopoietic
modulating activity, for example: transforming growth factor b1
(TGF- b1) and interleukin 9 (IL-9) have been found to have multi-
ple effects during early and late stages of myelopoiesis. Based on the
inhibition of CFU-IL3 observed after co-culture of BMC with anti-
CD3/CD281IL-2 activated Tregs, we hypothesize that this regula-
tion occurs in a contact dependent manner through a mechanism
involving TGF-b1. Inhibition was not observed in transwell cul-
tures and we found that Tregs fail to inhibit CFU-IL3 activity
from MHC class II deficient BMC in vitro. Interestingly, CFU-
IL3 numbers were enhanced following transplant of syngeneic
B6-wt but not B6-Class II-/- BM in lethally conditioned recipients
depleted of Tregs, further supporting the notion that cognate inter-
action is required for this negative regulation to take place. IL-9 is
a T cell factor which can promote both growth and survival signals
capable of augmenting erythroid progenitor cell (PC) activity. Acti-
vated Treg cells co-cultured with syngeneic BMC populations as
well as Lin- fractions routinely resulted in a 3–4  augmentation
of CFU-E vs. control cultures lacking Tegs. Anti-IL-9 specific
mab but not isotype control Ig abolished the enhancement of
CFU-E activity. Moreover, Tregs from IL-9 KO mice inhibited
